By Saskatchewan Health Research Foundation - October 21, 2010 |

On October 19, 2010, the Government of Saskatchewan made $5M available to SHRF to fund clinical trials for the MS liberation treatment.
To download a copy of the October 19th, 2010 media release announcement, click here.

Watch this area of our web site for ongoing updates as this call for proposals and granting process moves forward.

SHRF will provide the money in stages to a top-quality research team to be chosen in a competitive grant review process based on accepted standards of science, ethics and clinical care. We will manage the grant funds according to our well-established grants management processes.

- FIRST STEP – SHRF will form an expert advisory panel to assist in developing criteria for a call for research proposals and in overseeing the selection process. The advisory panel will be convened in early November.

- The panel will consist of about six people from Saskatchewan and other jurisdictions. It will include clinical specialists, research experts, and a patient advocate. Possible areas of expertise to be included are neurology, vascular surgery, interventional radiology, rehabilitation therapies, and clinical trials design.

- SECOND STEP – An expedited call for proposals will be based on sound evidence and best practices. A call for proposals typically outlines the scope of the research, funding available, timelines, application requirements, and criteria for success. SHRF’s goal is to issue a call for proposals early in December.

- THIRD STEP – An expert peer-review committee will assess all proposals submitted to SHRF in response to the call and provide its funding recommendation in early spring 2011. SHRF expects to announce the outcome of the competition in April 2011.

- The successful research team will include clinicians and scientists comprising expertise in designing and managing clinical trials, providing medical care for patients with multiple sclerosis, and leading a multi-disciplinary, multi-site research team. Given the focus on Saskatchewan patients, a portion of the research team will be from Saskatchewan. Team members will have a demonstrated record of excellence in their fields.

Read more...